Souhaitez-vous accéder aux communiqués récents ?

Longeveron granted Canadian patent for method of using stem cells to treat patients with aging-related frailty and also for the treatment of NIDCM.

Longeveron presents new MRI biomarker data linking neuroinflammation to clinical outcomes in patients with mild Alzheimer's disease at CTAD 2025.

Cellular therapy laromestrocel Phase 2 clinical trial data in Alzheimer's disease selected for poster presentation at CTAD 2025.

Longeveron issued US patent for method of treating aging-related frailty in patients with inflammaging using its proprietary stem cell therapy.

Dublin, Nov. 10, 2025 (GLOBE NEWSWIRE) -- The "Induced Pluripotent Stem Cells Market Report by Derived Cell Type, Application, End User, Countries and Company Analysis, 2025-2033" has been added to ...

On track for top-line trial results in the third quarter of 2026 from pivotal Phase 2b clinical trial ELPIS II. ELPIS II is evaluating laromestrocel as a potential adjunct treatment for HLHS, a rare...

Dublin, Sept. 25, 2025 (GLOBE NEWSWIRE) -- The "Regenerative Drugs Market - Forecasts from 2025 to 2030" has been added to ResearchAndMarkets.com's offering. The Global Regenerative Drugs Market...

Dublin, Aug. 15, 2025 (GLOBE NEWSWIRE) -- The "Stem Cell Banking Market Report by Product Type, and Region 2025-2033" has been added to ResearchAndMarkets.com's offering. The global stem cell...

FDA approves Longeveron's Investigational New Drug (IND) application for stem cell therapy as a potential treatment for pediatric dilated cardiomyopathy.

Than Powell appointed as Longeveron CBO to lead overall business strategy, Alzheimer's program partnering and HLHS program international strategy.